Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CSF in Children and Adolescents With Muscular Dystrophy
NCT02814110Phase 1Unknown
- Sponsor
- Medical University of Białystok
- Start
- Mar 2013
- Primary completion
- Dec 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of filgrastim in muscular dystrophy (MD), sponsored by Medical University of Białystok. Primary endpoint: Adverse Events at 7 years. Status: unknown.
02
Drugs
filgrastim
03
Conditions
muscular dystrophy (MD)
Beyond the preview
Go deeper on NCT02814110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02814110.